RIGEL PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Jane Wasman

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jane Wasman”): 10,380,140 for, 387,223 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2028 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 3,650,123 for, 39,111 against, 8,866 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Election of Directors: Kamil Ali-Jackson

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kamil Ali-Jackson”): 10,542,422 for, 227,808 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2028 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 3,657,761 for, 31,473 against, 8,866 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 700,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 6,856,776 for, 3,591,569 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 2,764,297 for, 924,937 against, 8,866 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 9,388,816 for, 993,913 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 58 managers: 3,620,057 for, 66,903 against, 8,866 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 131 managers: 6,233,276 for, 247,105 against, 137 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

The 59 asset managers below reported 3,426,043 for, 263,191 against, 8,866 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.